MedPage Today on MSN
Livers of MASLD Patients End Up Less Fatty With Novel Injectable
No drugs are specifically indicated for MASLD, but the FDA has granted accelerated approval to two drugs for non-cirrhotic ...
Zacks Small Cap Research on MSN
MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025…
MTVA READ THE FULL MTVA RESEARCH REPORT Business Update 8-Week Data for DA-1726 48 mg Cohort Expected in 4Q25 MetaVia, Inc.
Cite this: Receptor for Advanced Glycation End Products: Its Role in Alzheimer's Disease and Other Neurological Diseases - Medscape - Mar 31, 2009. Disclosure: The authors have no other relevant ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.
Prescriptions for GLP-1 receptor agonists in cancer patients have increased despite lack of clinical guidance. The overall ...
Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback